SCHEMBL3577428

SCHEMBL3577428

COc1ccc(CCCN(C)C)c([N+](=O)[O-])c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.51
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 1/20 0.46
POLB P06746 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
NQO1 P15559 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HTR2A P28223 2/20 0.42
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HTR6 P50406 2/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
CYP1A2 P05177 1/20 0.41
HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4233857 0.82 ALDH1A1 (0.48) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL3582642 0.82 ALDH1A1 (0.49) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL3823448 0.80 ALDH1A1 (0.54) ALDH1A1MAPK1POLBMCOLN3SMN1; SMN2
SCHEMBL5224397 0.79 TAAR1 (0.54) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL3576116 0.79 ALDH1A1 (0.51) ALDH1A1MAPK1POLBMCOLN3SMN1; SMN2
SCHEMBL2946382 0.79 ALDH1A1 (0.51) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL3574940 0.79 ALDH1A1 (0.50) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL28712089 0.79 ALDH1A1 (0.53) ALDH1A1MAPK1POLBMCOLN3SMN1; SMN2
Ammonia Solution, Strong SCHEMBL11258422 0.78 TAAR1 (0.53) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL5219494 0.77 ALDH1A1 (0.52) ALDH1A1MAPK1POLBSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118076-B1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO SA (CH) 2019-09-04 EP disclosed
US-8614215-B2 Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) MERCK SERONO SA (CH) 2013-12-24 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
US-20100137308-A1 Quinoxaline Compounds and Use Thereof MERCK SERONO SA (CH) 2010-06-03 US disclosed
EP-2118076-A1 QUINOXALINE COMPOUNDS AND USE THEREOF Merck Serono S.A. (CH) 2009-11-18 EP disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137308-A1 Quinoxaline Compounds and Use Thereof PFKP, PDXK, PF4 SLC6A4 866/4885ALDH1A1 577/4885MAPK1 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.